Edition:
United States

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

79.42EUR
10:31am EST
Change (% chg)

€-0.79 (-0.98%)
Prev Close
€80.21
Open
€79.62
Day's High
€80.29
Day's Low
€79.14
Volume
1,035,314
Avg. Vol
2,458,598
52-wk High
€80.44
52-wk Low
€62.88

Select another date:

Mon, Nov 12 2018

BRIEF-Sanofi: Analyses On Mortality From ODYSSEY OUTCOMES Trial Of Praluent

* ANNOUNCED ON SUNDAY ANALYSES ON MORTALITY FROM THE 18,924-PATIENT ODYSSEY OUTCOMES TRIAL

Sanofi and Regeneron's Dupixent gets more positive feedback from U.S. FDA

PARIS The U.S. Food & Drug Administration (FDA) regulator has given more positive feedback on the Dupixent eczema treatment being developed by drugmakers Sanofi and Regeneron, the companies said on Tuesday.

UPDATE 1-Sanofi and Regeneron's Dupixent gets more positive feedback from U.S. FDA

PARIS, Nov 6 The U.S. Food & Drug Administration (FDA) regulator has given more positive feedback on the Dupixent eczema treatment being developed by drugmakers Sanofi and Regeneron, the companies said on Tuesday.

Sanofi and Regeneron's Dupixent gets more positive feedback from U.S. FDA - companies

PARIS, Nov 6 The U.S. Food & Drug Administration (FDA) regulator gave more positive feedback on the Dupixent eczema treatment being developed by drugmakers Sanofi and Regeneron, the companies said on Tuesday.

Vaccines and Genzyme help Sanofi keep promise of return to growth

PARIS Sanofi lifted its 2018 profit target for the second time this year after robust sales of its vaccines and rare diseases division, Genzyme, helped it beat third-quarter profit expectations.

UPDATE 2-Vaccines and Genzyme help Sanofi keep promise of return to growth

PARIS, Oct 31 Sanofi lifted its 2018 profit target for the second time this year after robust sales of its vaccines and rare diseases division, Genzyme, helped it beat third-quarter profit expectations.

Vaccines and Genzyme help Sanofi keep promise of return to growth

PARIS, Oct 31 Sanofi narrowed its 2018 profit target for the second time this year after it posted higher-than-expected third-quarter profits, helped by robust sales growth at its key vaccines unit and its rare diseases Genzyme division.

Sanofi drug Dupixent wins FDA approval to treat asthma

France's Sanofi SA said on Friday eczema drug Dupixent was approved by the U.S. Food and Drug Administration as an additional maintenance therapy in patients with two types of asthma.

CORRECTED-Sanofi drug Dupixent wins U.S. FDA approval to treat asthma

Oct 19 France's Sanofi SA said on Friday eczema drug Dupixent was approved by the U.S. Food and Drug Administration as an additional maintenance therapy in patients with two types of asthma.

Sanofi, Regeneron say late-stage Dupixent trials show positive results

PARIS, Oct 16 Drugmakers Sanofi and Regeneron said on Tuesday that they received positive results for their Dupixent product, which treats eczema and is seen as a key driver of future revenues.

Select another date: